Ticker >

Dr. Lal Pathlabs share price

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB BSE: 539524 SECTOR: Hospital & Healthcare Services  187k   1k   307

2335.00
+5.35 (0.23%)
BSE: Today, 12:50 PM

Price Summary

Today's High

₹ 2376.05

Today's Low

₹ 2250.15

52 Week High

₹ 2766.85

52 Week Low

₹ 1762.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

19492.08 Cr.

Enterprise Value

19194.53 Cr.

No. of Shares

8.35 Cr.

P/E

53.21

P/B

10.27

Face Value

₹ 10

Div. Yield

0.51 %

Book Value (TTM)

₹  227.4

CASH

534.22 Cr.

DEBT

236.67 Cr.

Promoter Holding

54.6 %

EPS (TTM)

₹  43.88

Sales Growth

-5.84%

ROE

19.19 %

ROCE

22.71%

Profit Growth

-15.32 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 20 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5.84%
3 Year11.58%
5 Year11.55%

Profit Growth

1 Year-15.32%
3 Year9.42%
5 Year11.68%

ROE%

1 Year19.19%
3 Year23.92%
5 Year23.79%

ROCE %

1 Year22.71%
3 Year29.94%
5 Year31.35%

Debt/Equity

0.145

Price to Cash Flow

45.59

Interest Cover Ratio

12.3668673472356

CFO/PAT (5 Yr. Avg.)

1.27745288419446

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 54.6 0
Sep 2023 54.61 0
Jun 2023 55.01 0
Mar 2023 55.03 0
Dec 2022 55.05 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 108.752 Cr.
  • Company has been maintaining healthy ROE of 23.9202440214243% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.9354248154394% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 12.3668673472356.
  • The Company has been maintaining an effective average operating margins of 26.1330133085895% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -103.516810656563 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.27745288419446.
  • The company has a high promoter holding of 54.6%.

 Limitations

  • The company has shown a poor profit growth of 9.41744507309754% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.5750613133357% for the Past 3 years.
  • The company is trading at a high PE of 53.21.
  • The company is trading at a high EV/EBITDA of 31.6129.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 429.4 431 480.1 531.7 476
Total Expenditure 324.7 315.3 344.3 368.7 345.9
Operating Profit 104.7 115.7 135.8 163 130.1
Other Income 8.6 11.6 15 14.1 15.1
Interest 8.3 8.4 7.3 7.1 6.5
Depreciation 20.8 20.8 18.4 19.1 19.2
Exceptional Items 0 0 0 0 0
Profit Before Tax 84.2 98.1 125.1 150.9 119.5
Tax 21.6 26.7 31.5 37.9 31.2
Profit After Tax 62.6 71.4 93.6 113 88.3
Adjusted EPS (Rs) 7.51 8.56 11.22 13.53 10.57

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1164.9 1273.6 1490.56 1878.79 1769.03
Total Expenditure 882.1 945.79 1083.18 1366.32 1308.33
Operating Profit 282.8 327.81 407.38 512.47 460.7
Other Income 46.49 57.61 51.27 53.1 46.6
Interest 0.74 14.66 14.83 28.63 34.38
Depreciation 36.18 68.01 69.78 75.94 82.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 292.37 302.75 374.04 460.99 390.83
Tax 96.93 79.57 93.94 115.74 98.47
Net Profit 195.44 223.18 280.11 345.25 292.36
Adjusted EPS (Rs.) 23.45 26.78 33.61 41.42 35.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 83.34 83.35 83.35 83.35 83.37
Total Reserves 847.49 932.94 1133.74 1388.77 1606.5
Borrowings 0 0 0 166.67 83.33
Other N/C liabilities -19.86 68.18 76.83 90.73 82.26
Current liabilities 134.46 211.29 252.25 451.04 432.16
Total Liabilities 1045.43 1295.75 1546.16 2180.55 2287.62
Assets
Net Block 172.96 296.53 300.07 370.95 361.48
Capital WIP 2.87 10.3 5.51 14.45 2.97
Intangible WIP 0 0.99 3.48 0 1.97
Investments 32.37 93.88 120.4 1061.81 1072.03
Loans & Advances 16.24 18.43 23.87 24.33 19.89
Other N/C Assets 24.77 13.21 3.53 9.71 19.11
Current Assets 796.23 862.41 1089.3 699.31 810.17
Total Assets 1045.43 1295.75 1546.16 2180.55 2287.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 292.37 302.75 374.04 460.99 390.83
Adjustment 8.85 45.84 59.1 87.81 96.31
Changes in Assets & Liabilities 9.66 12.57 37.33 -5.55 39.52
Tax Paid -102.38 -89.17 -97.12 -117.53 -99.13
Operating Cash Flow 208.5 271.99 373.36 425.73 427.53
Investing Cash Flow -92.75 -19.47 -195.19 -448.53 -288.47
Financing Cash Flow -54.33 -187.22 -135.74 141.24 -270.05
Net Cash Flow 61.43 65.3 42.42 118.43 -130.99

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 55.05 55.03 55.01 54.61 54.60
anjaneya lal 2.03 2.03 2.03 2.02 2.02
archana lal erdmann 2.03 2.03 2.03 2.03 2.03
arvind lal 31.69 31.69 31.67 31.29 31.28
vandana lal 19.29 19.29 19.28 19.27 19.27
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 44.95 44.97 44.99 45.39 45.40
al mehwar commercial inve... 1.06 1.06 1.06 - 1.06
first sentier investors i... - - - - 1.14
invesco oppenheimer inter... - 2.92 2.89 2.89 2.69
life insurance corporatio... 1.48 1.48 1.48 1.48 1.47
llp 0.07 0.07 0.06 0.05 0.04
om prakash manchanda 1.45 1.39 1.28 1.25 1.23
uti flexi cap fund 2.06 2.27 2.81 2.96 2.97
wasatch emerging india fu... - - - - 1.02
al mehwar commercial inv... - - - 1.06 -
first sentier investors i... - - - 1.14 -
first sentier investors i... - 1.14 1.14 - -
westbridge crossover fund... 2.00 1.83 - - -
invesco oppenheimer inter... 3.07 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Lal PathLabs informs about earnings presentation1 Feb 2024, 3:46PM Dr. Lal Pathlabs - Quaterly Results1 Feb 2024, 1:30PM Dr. Lal Pathlabs - Quaterly Results1 Feb 2024, 1:30PM Dr. Lal Pathlabs - Quaterly Results1 Feb 2024, 1:30PM Dr. Lal PathLabs informs about conference call25 Jan 2024, 2:34PM Dr. Lal PathLabs informs about board meeting 25 Jan 2024, 2:22PM Dr. Lal PathLabs informs about closure of trading window25 Jan 2024, 12:34PM Dr. Lal PathLabs informs about allotment of equity shares under ESOP17 Nov 2023, 2:30PM Dr. Lal Pathlabs - Quaterly Results2 Nov 2023, 1:37PM Dr. Lal Pathlabs - Quaterly Results2 Nov 2023, 1:37PM Dr. Lal Pathlabs - Quaterly Results2 Nov 2023, 1:37PM Dr. Lal PathLabs informs about analyst meet 15 Sep 2023, 12:12PM Dr. Lal PathLabs informs about AGM 17 Aug 2023, 5:16PM Dr. Lal PathLabs informs about BRSR 17 Aug 2023, 5:10PM Dr. Lal PathLabs informs about transcript of conference call2 Aug 2023, 12:53PM Dr. Lal Pathlabs - Quaterly Results27 Jul 2023, 2:28PM Dr. Lal Pathlabs - Quaterly Results27 Jul 2023, 2:28PM Dr. Lal Pathlabs - Quaterly Results27 Jul 2023, 2:28PM Dr. Lal PathLabs submits board meeting intimation20 Jul 2023, 12:52PM Dr. Lal PathLabs informs about trading window closure30 Jun 2023, 10:39AM Dr. Lal PathLabs informs about analyst meet9 Jun 2023, 11:04AM Dr. Lal PathLabs informs about analyst meet5 Jun 2023, 5:10PM Dr. Lal PathLabs submits analyst meet intimation2 Jun 2023, 4:44PM Dr. Lal PathLabs informs about analyst meet 16 May 2023, 10:27AM Dr. Lal PathLabs submits analyst meet intimation15 May 2023, 5:03PM Dr. Lal Pathlabs reports 8% fall in Q4 consolidated net profit 11 May 2023, 4:51PM Dr. Lal Pathlabs - Quaterly Results11 May 2023, 2:04PM Dr. Lal Pathlabs - Quaterly Results11 May 2023, 2:04PM Dr. Lal Pathlabs - Quaterly Results11 May 2023, 2:04PM Dr. Lal PathLabs informs about conference call8 May 2023, 12:45PM Dr. Lal PathLabs submits analyst meet intimation30 Mar 2023, 3:43PM Dr. Lal PathLabs submits analyst meet intimation27 Mar 2023, 2:44PM Dr. Lal PathLabs informs about institutional investor meeting23 Mar 2023, 10:41AM Dr. Lal PathLabs informs about resignation of company secretary 21 Mar 2023, 1:14PM Dr. Lal PathLabs informs about analyst meet 17 Mar 2023, 10:45AM Dr. Lal PathLabs selects Kyndryl to manage IT infrastructure stack15 Mar 2023, 3:08PM Dr. Lal PathLabs informs about analyst meet 15 Mar 2023, 9:54AM Dr. Lal PathLabs informs about analyst meet 2 Mar 2023, 3:12PM Dr. Lal PathLabs informs about analyst meet 23 Feb 2023, 12:31PM Dr. Lal PathLabs informs about analyst meet 17 Feb 2023, 10:09AM Dr. Lal PathLabs informs about analyst meet7 Feb 2023, 3:17PM Dr. Lal PathLabs informs about institutional investor meeting6 Feb 2023, 4:58PM Dr. Lal Pathlabs - Quaterly Results2 Feb 2023, 2:16PM Dr. Lal Pathlabs - Quaterly Results2 Feb 2023, 2:16PM Dr. Lal Pathlabs - Quaterly Results2 Feb 2023, 2:16PM Dr. Lal Pathlabs’ arm gets nod to acquire further 10% stake in APRL PathLabs31 Jan 2023, 10:00AM Dr. Lal PathLabs informs about analyst meet intimation27 Jan 2023, 3:04PM Dr. Lal PathLabs informs about closure of trading window28 Dec 2022, 3:59PM Dr. Lal PathLabs informs about analyst meet 7 Dec 2022, 5:09PM Dr. Lal PathLabs informs about analyst meet5 Dec 2022, 3:23PM

Dr. Lal Pathlabs Stock Price Analysis and Quick Research Report. Is Dr. Lal Pathlabs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Lal Pathlabs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dr. Lal Pathlabs cash from the operating activity was Rs 427.531 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Lal Pathlabs has a Debt to Equity ratio of 0.145 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Lal Pathlabs , the EPS growth was -15.3440226338939 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Lal Pathlabs has OPM of 26.0425770054776 % which is a good sign for profitability.
     
  • ROE: Dr. Lal Pathlabs have a average ROE of 19.1929088950971 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dr. Lal Pathlabs is Rs 2328.1. One can use valuation calculators of ticker to know if Dr. Lal Pathlabs share price is undervalued or overvalued.
Last Updated on:
Brief about Dr. Lal Pathlabs

Dr. Lal Pathlabs Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Dr. Lal Pathlabs Ltd. is a leading provider of diagnostic healthcare services in India. Long-term investors interested in investing in healthcare companies need to conduct a comprehensive stock analysis of Dr. Lal Pathlabs Ltd. The analysis should include essential factors like balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Dr. Lal Pathlabs Ltd. Share Price

The share price of Dr. Lal Pathlabs Ltd. is a crucial factor to consider when analyzing the company for long-term investment. The share price is influenced by various factors, including market trends, financial performance, and investor sentiment. Ticker pre-built screening tools provide real-time updates on the share price of Dr. Lal Pathlabs Ltd., helping investors stay informed about price fluctuations and market trends.

Dr. Lal Pathlabs Ltd. Balance Sheet

Analyzing the balance sheet of Dr. Lal Pathlabs Ltd. is essential to understand the financial stability and performance of the company. The balance sheet provides a snapshot of the company's assets, liabilities, and shareholders' equity. Dr. Lal Pathlabs Ltd.'s balance sheet is analyzed using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, allowing investors to calculate fair value based on the balance sheet.

Dr. Lal Pathlabs Ltd. Annual Report

Dr. Lal Pathlabs Ltd. annual report provides comprehensive details about the company's financial performance, strategic initiatives, and future prospects. Investors can access and download the annual report directly from Ticker to gain a deeper understanding of Dr. Lal Pathlabs Ltd.'s performance and make well-informed investment decisions.

Dr. Lal Pathlabs Ltd. Dividend

Dr. Lal Pathlabs Ltd. provides dividends as a way to share its profits with shareholders. Dividends are a crucial consideration for long-term investors, as they demonstrate the company's commitment to returning value to shareholders. By monitoring dividend payments through Ticker pre-built screening tools, investors can stay updated on the latest dividend announcements and assess the company's dividend history.

Dr. Lal Pathlabs Ltd. Quarterly Results

Analyzing the quarterly results of Dr. Lal Pathlabs Ltd. provides crucial information about the company's growth and profitability over specific periods. By monitoring revenue, expenses, and profits, investors can assess the company's performance and make informed investment decisions. Dr. Lal Pathlabs Ltd.'s financial information is analyzed using tools like Earnings multiple approaches and DuPont analysis, enabling long-term investors to make informed investment decisions.

Dr. Lal Pathlabs Ltd. Stock Price

The stock price of Dr. Lal Pathlabs Ltd. is influenced by various factors, including market trends, financial performance, and investor sentiment. Tracking the stock price helps investors gain insights into the market's reaction to the company's performance and news. Ticker pre-built screening tools provide real-time updates on the stock price of Dr. Lal Pathlabs Ltd., allowing investors to stay informed about price movements and make well-informed decisions.

Dr. Lal Pathlabs Ltd. Price Chart

The price chart of Dr. Lal Pathlabs Ltd. visually represents the historical trends of the stock price. By analyzing the chart, long-term investors can identify patterns and trends that may impact future stock performance. The price chart is a valuable tool for assessing the potential investment value of Dr. Lal Pathlabs Ltd. and making informed decisions.

Dr. Lal Pathlabs Ltd. News

Staying updated with the latest news about Dr. Lal Pathlabs Ltd. is crucial for long-term investors conducting a stock analysis. Ticker provides access to the company's news, including press releases, analyst reports, and market updates. This ensures investors can keep track of changes and developments in the company and make informed investment decisions.

Dr. Lal Pathlabs Ltd. Concall

Participating in Dr. Lal Pathlabs Ltd.'s concall allows investors to hear directly from the management team. The concall offers valuable insights into the company's financial performance, strategic initiatives, and future plans. Investors can access the transcripts of the concall on Ticker, enabling them to review and refer to the discussions.

Dr. Lal Pathlabs Ltd. Transcripts

The transcripts of Dr. Lal Pathlabs Ltd.'s concall provide a detailed account of the discussions between the management team, analysts, and investors. These transcripts contain valuable information that aids in investment analysis and decision-making.

Dr. Lal Pathlabs Ltd. Investor Presentations

Dr. Lal Pathlabs Ltd.'s investor presentations provide an in-depth overview of the company's operations, future prospects, and growth strategy. By reviewing these presentations, investors can gain insights into Dr. Lal Pathlabs Ltd.'s long-term plans and evaluate its potential as an investment opportunity.

Dr. Lal Pathlabs Ltd. Promoters

Identifying the promoters of Dr. Lal Pathlabs Ltd. provides insights into the management team's involvement and influence over the company. Understanding the promoters helps in analyzing the company's ownership structure and potential conflicts of interest.

Dr. Lal Pathlabs Ltd. Shareholders

Analyzing the shareholder base of Dr. Lal Pathlabs Ltd. provides investors with insights into the company's ownership structure. Understanding the distribution of shares among various shareholders helps assess its potential impact on the company's stock performance and governance.

Read More
X